Affordable Access

deepdyve-link
Publisher Website

Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial.

Authors
  • Blauw, Helga1, 2
  • Onvlee, A Joannet2, 3
  • Klaassen, Michel2
  • van Bon, Arianne C3
  • DeVries, J Hans4
  • 1 Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands [email protected] , (Netherlands)
  • 2 Inreda Diabetic, Goor, the Netherlands. , (Netherlands)
  • 3 Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands. , (Netherlands)
  • 4 Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. , (Netherlands)
Type
Published Article
Journal
Diabetes care
Publication Date
Jan 04, 2021
Identifiers
DOI: 10.2337/dc20-2106
PMID: 33397767
Source
Medline
Language
English
License
Unknown

Abstract

To demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes. In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient's normal insulin pump therapy with a glucose sensor if they had one). A total of 23 patients were included in the analysis. Time in range (70-180 mg/dL [3.9-10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9-88.5]) compared with open loop (53.9% [49.7-67.2]; P < 0.0001). Compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes. © 2021 by the American Diabetes Association.

Report this publication

Statistics

Seen <100 times